Topokine Sets Sail with Investment from Schooner Capital
January 24, 2013
Share:
Clinical-stage biotech Topokine Therapeutics has secured a round of financing from Schooner Capital. Headquartered in Newton, MA, the company develops therapies for dermatology and medical aesthetics. The deal will allow Topokine to advance its pipeline, which includes a clinical-stage skin cream known as XAF5 Gel used for local reduction of excess subcutaneous fat. Schooner is a Boston-based investment firm that makes long-term commitments to private companies across several sectors.
